Hurel® Corporation Completes Investment from Johnston Associates
News Oct 08, 2014
Hurel Corporation has announced that Johnston Associates, Inc. of Princeton, New Jersey (“JAI”) has become a participating investor in the Company’s Series A-3 Preferred Stock financing. Hurel’s lead private equity investor, Spring Mountain Capital, LP, of New York, led the A-3 round.
“Johnston Associates is pleased to invest in Hurel, which is about to emerge as the leader in cell-based liver models,” Robert F. Johnston, JAI’s Managing Partner, said. “Hurel’s products have the capacity to improve and ultimately transform how preclinical drug discovery and general chemical testing are carried out. I’m looking forward to working with Hurel’s talented management team as they extend the commercial reach of their products and their company.”
Hurel CEO Robert Freedman commented, “As a founder of multiple, major biotech companies, Bob Johnston brings Hurel an immense resource of knowledge upon which we will be able to draw. It’s an honor and a pleasure to welcome Bob to Hurel’s investor family.”
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Rapid Test Helps with Administering the "Correct" DrugNews
In just three hours, a new rapid test will give information on which available antibiotic is still effective in a concrete case.READ MORE
Comments | 0 ADD COMMENT
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018
The Journey from Genes to Disease - a symposium for postdocs by postdocs.
Apr 20 - Apr 20, 2018